MarketsandMarkets ImmunoBio Series 2024

WHAT TO EXPECT

CUTTING-EDGE INSIGHTS: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
MULTIDISCIPLINARY LEARNING: Gain a comprehensive understanding of microbiome and probiotics research, exploring diverse topics and practical applications across healthcare, biotechnology, and food production.
INNOVATIVE IMMUNOTHERAPY: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
PROFESSIONAL DEVELOPMENT: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for microbiome and probiotics research.
PRACTICAL APPLICATIONS: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
PERSONAL AND INDUSTRY GROWTH: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research, microbiome studies, and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B - Next Gen Microbiome and Probiotics Conference

Stream C- Next Gen Immuno-Oncology Conference

Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

Exploring the Function of the Gut Microbiome and Modulation of Immune Cells
Role of human skin microbiome in precision health
Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy
Oral-Systemic Microbiome Connection and its Modulation
Modulating the Vaginal Microbiome for Women’s Health and Fertility
Mechanisms of Oncobiotic LBP candidate in Enhancing Cancer Immunotherapy
Microbiome as a science and its clinical applications- skin, gut & women’s health
Prebiotics, Probiotics and Postbiotics
Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer
Microbiome’s role in Cancer

Preclinical and Translational Immuno-Oncology Developments
Next Gen Antibodies and Targeted Therapies
Immune Checkpoint Inhibitors and Combination Therapies
Tumor Microenvironment and Cancer Biomarkers
CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
Cancer Vaccines and Cancer Microbiome
Personalizing Cancer Treatment- Challenges and Opportunities

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation	09:00 - 09:30
Spatial Analysis in Ulcerative Colitis and Crohn’s Disease Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb	09:30 - 10:00
Opportunities for biomarker development in neuroscience Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.	11:45 - 12:15
The crucial role of biospecimen management in precision medicine Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics	12:15 - 12:45
AI and Multimodal Biomarkers for Personalized Pain Medicine Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE
Identification of cancer cell surface target for antibody drug conjugate development Ginette Serrero, Chief Executive Officer, A&G Pharmaceutical, Inc. \| Precision Antibody	14:15 - 14:45
Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease Matteo D’Antonio, Assistant Professor, University of California, San Diego	14:45 - 15:15
Why is monitoring predictive biomarker data so difficult for big pharma?	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Patient Identification and Stratification Applying Predictive Models	16:30 - 17:00
Use of Real-World Evidence in discovery of digital biomarkers	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:35
Drinks, Reception & Networking	17:35 - 18:35

Opening Remarks from the Chairperson Julius Goepp, Founder, CEO, Scaled Microbiomics	08:55 - 09:00
UNVEILING TOMORROW’S HEALTH WITH NEW MICROBIOME FINDINGS
Keynote Presentation	09:00 - 09:30
Interpreting Microbiomes via Multi-Omics in Health, Disease, Aging, and Drug Responses Julius Goepp, Founder, CEO, Scaled Microbiomics	09:30 - 10:00
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
TBA, Senior Representative, Biolog TBA, Senior Representative, Biolog, ,	11:15 - 11:45
TBA, Senior Representative, Bioform Solutions TBA, Senior Representative, Bioform Solutions, ,	11:45 - 12:15
Oral-Systemic Microbiome Connection and its Modulation Emily Stein, CEO, Primal Health Inc.	12:15 - 12:45
Next-Generation Probiotics Against Enteric Pathogen Infection and Chronic Inflammatory Disease Arun K. Bhunia, Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
REVOLUTIONIZING WELLNESS – EXPLORING THE FUTURE OF MICROBIOME AND PROBIOTICS
How Lifestyle and Life Stages affect Gut Microbiota and the power of Biotics. Miguel Freitas, Vice President - Scientific Affairs, Danone	14:15 - 14:45
Effect of Lactobacillus Johnsonii 456 on Inflammation Caused Diseases, Cardiovascular Disease, Cancer, Diabetes and Obesity Robert Schiestl, Director and Manager, Microbio Pharma	14:45 - 15:15
Working with live probiotics – insights in developing effective skincare products from formulator’s perspective Maya Ivanjesku, Chief Scientific Officer, M2B Pharma	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Back to Health - An Evolutionary Biology Perspective on the Skin Microbiome	16:30 - 17:00
Modulation of the Aging Gut Microbiome to Improve Health	17:00 - 17:30
Closing Remarks from the Chairperson Julius Goepp, Founder, CEO, Scaled Microbiomics	17:30 - 17:35
Drinks Reception & Networking	17:35 - 18:35

NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT
Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1 Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:30 - 10:00
TBA, Senior Representative, Volition TBA, Senior Representative, Volition, ,	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Case Studies Leveraging 20,000 Digitized IO KM Curves – Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology Bruno Larvol, Founder & CEO, Larvol	11:15 - 11:45
Recombinant antibodies for Immunotherapy	11:45 - 12:15
Challenges in the clinical development of ADC’s	12:15 - 12:45
Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
DEVELOPMENTS IN CAR-T AND T-CELL THERAPIES PERSONALIZED IMMUNOTHERAPY
Solution Provider Presentation	14:15 - 14:45
Precision Immunology for targeted therapy	14:45 - 15:15
Role of Cancer Microbiome in IO	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
CAR-T cell therapy in solid tumours	16:30 - 17:00
Panel Discussions	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:35
Drinks Reception & Networking	17:35 - 18:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION
Keynote Presentation	09:00 - 09:30
Strategies to optimize CDx in cancer	09:30 - 10:00
Solution Provider Presentation	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Drug and CDx co-development with a therapeutic product	11:15 - 11:45
Solution Provider Presentation	11:45 - 12:15
CDx Launch Success: From Early Biomarker Development to Commercialization	12:15 - 12:45
Building up a successful CDx partnership with Pharma	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES
Leveraging IO markers for companion diagnostics development	14:15 - 14:45
Innovative Safety Biomarker Applications to Drug Development	14:45 - 15:15
Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx Julius Goepp, Founder, CEO, Scaled Microbiomics	15:15 - 15:45
Closing Remarks from the Chairperson	15:45 - 15:50
END OF CONFERENCE	15:50 - 15:50

Opening Remarks from the Chairperson Julius Goepp, Founder, CEO, Scaled Microbiomics	08:55 - 09:00
CULTIVATING WELLNESS: PIONEERING THE FUTURE OF MICROBIOME AND PROBIOTICS
Keynote Presentation Bruce Seal, Instructor, Biology, Oregon State University	09:00 - 09:30
Effective Microbiome Therapeutics in Production	09:30 - 10:00
Genetic Methods to Improve Lyophilization Survival in Bacteroides Kevin Roelofs, Principal Consultant, Greenbeard Consulting LLC	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Restoring Nitric Oxide: Prebiotic Nitrate and the Oral Microbiome Shawn Green, Founder, MyFitStrip	11:15 - 11:45
Probiotics from Idea to Shelf: Bringing a New Strain to Market Zachery Lewis, Probiotic/Prebiotic/Microbiome Expert,	11:45 - 12:15
Fiber Interventions and Cancer and Microbiome Kathrine Whiteson, Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences, University of California Irvine	12:15 - 12:45
Probiotics from Plants and its Key Benefits	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
EXPLORING THE INTERPLAY OF DIET, ANTIBODIES, AND IMMUNOTHERAPEUTIC STRATEGIES
Fine-Tuned Prebiotic Fiber Structures to Effective Support Probiotic-Type Bacteria	14:15 - 14:45
The Impact of Diet and Antibiotics on Colorectal Cancer and Immunotherapy	14:45 - 15:15
Panel Discussion	15:15 - 15:45
Closing Remarks from the Chairperson Julius Goepp, Founder, CEO, Scaled Microbiomics	15:45 - 15:50
END OF CONFERENCE	15:50 - 15:50

Keynote Presentation	09:00 - 09:30
PRECLINICAL AND TRANSLATIONAL IMMUNO-ONCOLOGY UPDATES- NEW CHECKPOINTS FOR IO
Pre-clinical models for Immune checkpoint modulators	09:30 - 10:00
Solution Provider Presentation	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Translational approach in developing right IO therapy	11:15 - 11:45
Solution Provider Presentation	11:45 - 12:15
Development of new generation DNA vaccines	12:15 - 12:45
Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
CANCER MICROBIOME AND IMMUNOTHERAPY: PARTNERS IN PERSONALIZED CANCER CARE
Future opportunities in clinical development of ICI’s	14:15 - 14:45
The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms	14:45 - 15:15
Panel Discussion Paul (Weibing) Shi, Principal Scientist, NGS & Infrastructure Lead, Amgen	15:15 - 15:45
Closing Remarks from the Chairperson	15:45 - 15:50
END OF CONFERENCE	15:50 - 15:50

SPEAKERS

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Sahil Khanna

Professor of Medicine, Chair GI Hospital Practice, Associate Program Director Internal Medicine Residency Program, Medical Director Desk and Secretarial Operations, Mayo Clinic

Shawn Green

Founder, MyFitStrip

John Kirby

Chair of Microbiology & Immunology at MCW | Co-Founder, Rose Biosciences

Zachery Lewis

Probiotic/Prebiotic/Microbiome Expert,

TBA, Senior Representative, Biolog

TBA, Senior Representative, Bioform Solutions

Antonio Gomes

Principal Scientist, Xbiome

Christopher Damman

Senior Medical & Scientific Advisory Board Member, BCD Bioscience

TBA, Senior Representative, Helaina

Tariq Warsi

Vice President, Novome Biotechnologies

Robert Schiestl

Director and Manager, Microbio Pharma

Bruce Seal

Instructor, Biology, Oregon State University

Marina Santiago

Director of Research and Development, FitBiomics

TBA, Senior Representative, Sanyou Bio

TBA, Senior Representative, TransCure Services

TBA, Senior Representative, Veracyte

TBA, Senior Representative, Biocytogen

TBA, Senior Representative, Volition

Bruno Larvol

Founder & CEO, Larvol

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor

Paul Kassner

Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

Jack SH Chen

Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie

Daud Adil

Director, Melanoma Program, UCSF Medical Center

Collin

Scientist, EpigenDx

Matt Giacalone

CEO, Vaxiion Therapeutics

Nur Hasan

Chief Executive Officer, EzBiome Inc

Kareem Barghouti

Co-Founder, VastBiome

Paul (Weibing) Shi

Principal Scientist, NGS & Infrastructure Lead, Amgen

Charles Joel Rosser

Medical Director, Cedars-Sinai

Jiangwei Zhang

Senior Principal Scientist, Bristol Myers Squibb

Ranjan Perera

Associate Professor, Johns Hopkins University

Carl Saab

Professor, Innovation Lead Digital Health, Cleveland Clinic

Nicole Miller

Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

Jakob Dupont

Executive Partner, Sofinnova Ventures

Pablo Lapuerta

Chief Executive Officer, 4M Therapeutics Inc.

Matteo D’Antonio

Assistant Professor, University of California, San Diego

Julius Goepp

Founder, CEO, Scaled Microbiomics

Ayat Alsaraby

Sr. Manager, Clinical Biomarker, Repare Therapeutics

Miguel Freitas

Vice President - Scientific Affairs, Danone

Vandana Sharma

Principal Nutrition Scientist, Pharmavite

Larry Weiss

CEO and Founder, Symbiome

Maya Ivanjesku

Chief Scientific Officer, M2B Pharma

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Emily Stein

CEO, Primal Health Inc.

Lada Rasochova

CEO, Dermala

Kathrine Whiteson

Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences, University of California Irvine

Ginette Serrero

Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

Grab before it's gone. Avail 30% Instant Discount

ImmunoBio Series 2024 - West Coast Edition

Bridging Science, Innovation, and Health for a Better Tomorrow

CO-LOCATED CONFERENCES